抗结核药物的挑战  

The challenges of anti-tuberculosis drugs

作　　者：郭茹[1] 聂文娟[1] 王隽[1] 杜亚东[1] 荆玮[1] 初乃惠[1] GUO Ru;NIE Wen-juan;WANG Jun;DU Ya-dong;JING Wei;CHU Nai-hui(Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University, Beijing 101149, China)

机构地区：[1]首都医科大学附属北京胸科医院结核一科,北京101149

出　　处：《临床药物治疗杂志》2018年第4期4-8,共5页Clinical Medication Journal

摘　　要：WHO在2006年将结核病药物分为5组。为适应分子生物学的发展,2016年又将药物分为4组,将氯法齐明和利胺唑胺作为核心药物。目前有8个药物在开展临床试验,其中2个为新的化合物。治疗敏感结核的有利福喷丁和莫西沙星,治疗耐药结核病的有上市药品,如利奈唑胺、氯法齐明、环丝氨酸等。已上市的新型化合物有贝达喹啉和利奈唑胺,还有未上市的如PA-824、TBA-354、sutezolid、AZD5847、SQ-109等,这些药物的逐渐上市为耐药结核病治疗提供了强大的武器。WHO divided TB drugs into 5 groups in 2006. In order to adapt to the development of molecular biology, the TB drugs were divided into 4 groups in 2016, clofazimine and linezolid were divided as core drugs. Currently, there are 8 drugs in clinical trials, of which 2 are new compounds. Rifabutin and moxifloxacin for the treatment of sensitive tuberculosis, and marketed drugs for the treatment of drug-resistant tuberculosis, such as linezolid, clofazimine and cycloserine and so on. New compounds that have been approved include bedaquiline and linezolid, as well as unapproved drugs such as PA-824, TBA-354, sutezolid, AZD5847, and SQ-109 and so on, the gradual listing of these drugs provides a powerful weapon for the treatment of drug-resistant tuberculosis.

关 键 词：结核 耐药 新药 分类 

分 类 号：R978.3[医药卫生—药品]